News AZ's chief medical officer Bohen quits after shake-up AstraZeneca’s chief medical officer Sean Bohen is to leave the company following its organisational shake-up.
News Lilly further boosts cancer pipeline with $8bn Loxo acquisit... In the second big M&A deal of the year following BMS’s acquisition
News Takeda strikes three new immuno-oncology deals Takeda is upping its commitment to cancer after its Shire takeover with the announcement of three new research collaborations in immuno-oncology.
Events Partner Content The Pharma Forecasting Workshop - Fundamentals of Forecastin... J+D Interactive Pharma Forecasting Workshop
News Novartis oncology CEO quits after less than a year Novartis has appointed Susanne Schaffert to lead its oncology division after incumbent CEO Liz Barrett decided to leave for another job.
News AbbVie suffers fresh setback with lung cancer drug Rova-T AbbVie has suffered a further setback with its oncology drug Rova-T, after early data from a lung cancer trial suggested that patients were living longer when treated with standard therapy.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.